Merck Stock News

Merck & Co Inc (NYSE:MRK) is close to acquiring Harpoon Therapeutics Inc, a cancer drug developer, for about $700 million to bolster its oncology portfolio. The proposed deal, which could value Harpo

Merck MRK, +0.18% is in talks to buy cancer drugmaker Harpoon Therapeutics HARP, -1.49% for about $700 million, or $23 per share, Bloomberg News reported, citing people familiar with the matter. Merck

Merck & Co is in advanced talks to buy cancer drugmaker Harpoon Therapeutics Inc for around $700 million, Bloomberg News reported on Sunday, citing people familiar with the matter.

The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventi

The Health Care Select Sector SPDR Fund NYSEARCA: XLV, which has both growth and defensive characteristics, was the leader in the first week of the year. Top sector performers included Moderna Inc. NA

'Mad Money' host Jim Cramer talks stocks he is watching as the Magnificent 7 struggles in the new year.

Merck & Co's Chief Executive Officer Robert Davis said on Thursday the company is seeking GLP-1 treatments with benefits beyond weight loss.

In the latest trading session, Merck (MRK) closed at $114.77, marking a +1.35% move from the previous day.

It's a new year and apparently there's a new theme on Wall Street for investors. Many of the Magnificent Seven stocks and their high-flying tech peers are off to a difficult start in 2024.

The Weekly MDA Breakouts completed the best year since this model was released on Seeking Alpha in 2017. In 2023, 125 picks gained over 5% and 65 picks gained over 10% in their measured week, with sim

The Dow is an excellent starting place if you are looking for foundational holdings. However, some Dow stocks would be best for investors to avoid right now.

Merck and Moderna are teaming up to make an advanced oncology drug. The candidate's clinical trials are proceeding swimmingly.

In the most recent trading session, Merck (MRK) closed at $107.98, indicating a +0.33% shift from the previous trading day.

With the possibility of an interest rate cut by the FED and fairly optimistic targets for the S&P 500 index by the largest analytical groups, investors might be looking for the best opportunities in t

Merck remains undervalued with a strong set of growing drugs and new indications in its pipeline. Keytruda has been a major revenue driver for MRK, with continued sales growth and potential for extend